Kelly E Caudle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5106859/publications.pdf

Version: 2024-02-01

30 3,809 20 29 papers citations h-index g-index 30 3654

30 30 30 3654 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on $\langle i \rangle \langle scp \rangle TPMT \langle scp \rangle \langle i \rangle$ and $\langle i \rangle \langle scp \rangle NUDT \langle scp \rangle 15 \langle i \rangle$ Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	4.7	428
2	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 2017, 19, 215-223.	2.4	410
3	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 210-216.	4.7	407
4	Standardizing <i><scp>CYP</scp>2D6</i> Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	3.1	353
5	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	1.2	341
6	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	4.7	244
7	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
8	The Clinical Pharmacogenetics Implementation Consortium: 10ÂYears Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	4.7	207
9	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for ⟨i⟩CYP2C9⟨/i⟩ and Nonsteroidal Antiâ€Inflammatory Drugs. Clinical Pharmacology and Therapeutics, 2020, 108, 191-200.	4.7	195
10	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2C19</i> Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
11	Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp> <i>2D6</i> Genotype and Atomoxetine Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 94-102.	4.7	152
12	The Clinical Pharmacogenetics Implementation Consortium Guideline for ⟨i⟩SLCO1B1⟨/i⟩, ⟨i⟩ABCG2⟨/i⟩, and ⟨i⟩CYP2C9⟨/i⟩ genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
13	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for ⟨i⟩CYP2C9⟨/i⟩ and ⟨i⟩HLAâ€B⟨/i⟩ Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
14	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 796-801.	4.4	83
15	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1977-1985.	1.0	79
16	Clinical Pharmacogenetics Implementation Consortium (<scp>CPIC</scp>) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of <i><scp>RYR</scp>1</i> or <i><scp>CACNA</scp>1S</i> Genotypes. Clinical Pharmacology and Therapeutics, 2019, 105, 1338-1344.	4.7	56
17	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	1.3	53
18	Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on ⟨i⟩MTâ€RNR1⟨ i⟩ Genotype. Clinical Pharmacology and Therapeutics, 2022, 111, 366-372.	4.7	50

#	Article	IF	Citations
19	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	2.4	49
20	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	4.7	22
21	Optimizing thiopurine dosing based on <i>TPMT</i> and <i>NUDT15</i> genotypes: It takes two to tango. American Journal of Hematology, 2019, 94, 737-740.	4.1	17
22	Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. Annual Review of Genomics and Human Genetics, 2022, 23, 449-473.	6.2	15
23	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	4.7	12
24	Response to "Impact of <i>CYP3A4</i> Genotype on Voriconazole Exposure: New Insights Into the Contribution of <i>CYP3A4*22</i> to Metabolism of Voriconazole― Clinical Pharmacology and Therapeutics, 2018, 103, 187-187.	4.7	11
25	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	1.0	10
26	Considerations for pharmacogenomic testing in a health system. Genetics in Medicine, 2019, 21, 1886-1887.	2.4	5
27	The impact of the <i>UGT1A1*60</i> allele on bilirubin serum concentrations. Pharmacogenomics, 2017, 18, 5-16.	1.3	4
28	Pharmacogenomics Education and Clinical Practice Guidelines., 2019,, 395-414.		2
29	Key considerations for using pharmacogenomics to optimize pain management. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 290-291.	1.5	2
30	Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacological Research, 2020, 158, 104838.	7.1	2